1. Xolair® Kısa Ürün Bilgisi 2. Boushey H. J Allergy Clin Immunol. 2001;108:S77-S83
1. Boushey H. J Allergy Clin Immunol 2001;108:S77–83; 2. Hochhaus G, et al. Curr Med Res Opin 2003;19:491–8; 3. Abbas AK, et al. Cellular and Molecular Immunology (4th edition) CH 19; 4. Zuberbier T, et al. Allergy 2009;64:1417–26.
1. SS Saini, et al. J Invest Dermatol. 2015 Jan; 135(1): 67–75
1. Maurer M, et al. N Engl J Med 2013 Mar 7;368(10):924-35
1. Xolair Kısa Ürün Bilgisi. (05.08.2016) 2. Maurer M, et al. N Engl J Med. 2013;368(10):924-35. Erratum in: N Engl J Med. 2013;368(24:2340-1. 3. Giménez-Arnau, Ana
M. "Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety." Expert opinion on biological therapy 17.3 (2017): 375-385. 4. Saini SS,
et al. J Invest Dermatol. 2015;135(1):67-75.